Long-term safety and tolerability of vardenafil in the treatment of erectile dysfunction
Objective: To assess the long-term safety and tolerability of vardenafil for patients with erectile dysfunction (ED).
Patients and methods: This was a multicentre, open-label, 24-month extension trial involving 1173 men with ED. The mean age was 57 (range 23-83) years and 74.8% of patients were taking concomitant medications for comorbid conditions, including diabetes mellitus in 30.5% of men and hypertension in 29.5%. These patients had participated in 1 of 5 previous 8-week or 12-week randomised, double-blind, placebo-controlled vardenafil studies. In the present trial, the starting 10mg dose of vardenafil could be increased to 20mg if the patient could not achieve satisfactory intercourse or reduced to 5mg for an adverse event that was persistent, intolerable and judged by the investigator to be related to vardenafil.
Results: Four hundred ninety-three (42.0%) men completed 24 months of treatment. In addition, a further 234 (19.9%) completed 18 months of treatment due to a sponsor decision to reduce the study duration. The total vardenafil exposure was 1676.0 patient-years. vardenafil was safe and well tolerated. Headache (15.8%), dyspepsia (11.8%), nasopharyngitis (11.4%), and back pain (8.2%) were the most common treatment-emergent adverse events. The rate of discontinuations due to adverse events for this 18-24-month study was 6.3% and the rate for any individual event was
Conclusion: vardenafil at doses of 5, 10, or 20mg taken as needed up to once daily for 18 to 24 months was safe and well tolerated. These findings support the long-term use of vardenafil in the clinical management of erectile dysfunction.
Similar articles
Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A. Eardley I, et al. BJU Int. 2004 Oct;94(6):871-7. doi: 10.1111/j.1464-410X.2004.05049.x. BJU Int. 2004. PMID: 15476525 Clinical Trial.
Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, Shen W, Whitaker JS. Porst H, et al. Eur Urol. 2006 Aug;50(2):351-9. doi: 10.1016/j.eururo.2006.02.052. Epub 2006 Mar 20. Eur Urol. 2006. PMID: 16766116 Clinical Trial.
Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM Jr, Hague JA, Ahuja S. Young JM, et al. J Androl. 2005 May-Jun;26(3):310-8. doi: 10.2164/jandrol.04126. J Androl. 2005. PMID: 15866997 Clinical Trial.
Bai WJ. Bai WJ. Zhonghua Nan Ke Xue. 2009 Jan;15(1):92-5. Zhonghua Nan Ke Xue. 2009. PMID: 19288756 Review. Chinese.
Liu ZY, Sun YH. Liu ZY, et al. Zhonghua Nan Ke Xue. 2008 Apr;14(4):377-80. Zhonghua Nan Ke Xue. 2008. PMID: 18481436 Review. Chinese.
Cited by
Chung JH, Kwon TG, Kwak C, Sung GT, Kim SD, Cho JS, Kim HJ, Ahn H, Jeon SS. Chung JH, et al. World J Mens Health. 2023 Jul;41(3):612-622. doi: 10.5534/wjmh.220057. Epub 2022 Sep 2. World J Mens Health. 2023. PMID: 36102102 Free PMC article.
Ferreira J, Levin LR, Buck J. Ferreira J, et al. Front Pharmacol. 2022 Aug 25;13:953903. doi: 10.3389/fphar.2022.953903. eCollection 2022. Front Pharmacol. 2022. PMID: 36091839 Free PMC article.
Kloner RA, Kostis JB, McGraw TP, Qiu C, Gupta A. Kloner RA, et al. J Clin Hypertens (Greenwich). 2022 Feb;24(2):167-178. doi: 10.1111/jch.14435. Epub 2022 Jan 31. J Clin Hypertens (Greenwich). 2022. PMID: 35099113 Free PMC article.
Theofilis P, Nakas N, Kalaitzidis RG. Theofilis P, et al. J Clin Hypertens (Greenwich). 2022 Feb;24(2):179-181. doi: 10.1111/jch.14433. Epub 2022 Jan 31. J Clin Hypertens (Greenwich). 2022. PMID: 35099103 Free PMC article. No abstract available.
Broffman L, Barnes M, Stern K, Westergren A. Broffman L, et al. JMIR Form Res. 2022 Jan 13;6(1):e32126. doi: 10.2196/32126. JMIR Form Res. 2022. PMID: 34905499 Free PMC article.
Kloner RA, Kostis JB, McGraw TP, Qiu C, Gupta A. Kloner RA, et al. J Clin Hypertens (Greenwich). 2022 Feb;24(2):167-178. doi: 10.1111/jch.14435. Epub 2022 Jan 31. J Clin Hypertens (Greenwich). 2022. PMID: 35099113 Free PMC article.
Long-term safety and tolerability of vardenafil in the treatment of erectile dysfunction
Objective: To assess the long-term safety and tolerability of vardenafil for patients with erectile dysfunction (ED).
Patients and methods: This was a multicentre, open-label, 24-month extension trial involving 1173 men with ED. The mean age was 57 (range 23-83) years and 74.8% of patients were taking concomitant medications for comorbid conditions, including diabetes mellitus in 30.5% of men and hypertension in 29.5%. These patients had participated in 1 of 5 previous 8-week or 12-week randomised, double-blind, placebo-controlled vardenafil studies. In the present trial, the starting 10mg dose of vardenafil could be increased to 20mg if the patient could not achieve satisfactory intercourse or reduced to 5mg for an adverse event that was persistent, intolerable and judged by the investigator to be related to vardenafil.
Results: Four hundred ninety-three (42.0%) men completed 24 months of treatment. In addition, a further 234 (19.9%) completed 18 months of treatment due to a sponsor decision to reduce the study duration. The total vardenafil exposure was 1676.0 patient-years. vardenafil was safe and well tolerated. Headache (15.8%), dyspepsia (11.8%), nasopharyngitis (11.4%), and back pain (8.2%) were the most common treatment-emergent adverse events. The rate of discontinuations due to adverse events for this 18-24-month study was 6.3% and the rate for any individual event was
Conclusion: vardenafil at doses of 5, 10, or 20mg taken as needed up to once daily for 18 to 24 months was safe and well tolerated. These findings support the long-term use of vardenafil in the clinical management of erectile dysfunction.
Conclusion: vardenafil at doses of 5, 10, or 20mg taken as needed up to once daily for 18 to 24 months was safe and well tolerated. These findings support the long-term use of vardenafil in the clinical management of erectile dysfunction.
Similar articles
Liu ZY, Sun YH.
01.06.2022 12:02:50
2022-06-01 12:02:50